TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2089092
Drug: MDL 72.974A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 72.974A (0.1-12 mg)
Study: 848665
Drug: Intraluminal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraluminal administration of 5-fluorouracil (5-FU)
Study: 848665
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 5-fluorouracil (5-FU)
Study: 848665
Drug: Intramural administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramural administration of 5-fluorouracil (5-FU)
Study: 848665
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) therapy (general)
Study: 28449281
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg varenicline
Study: 25847552
Drug: OMT+medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMT+medication therapy
Study: 23818409
Drug: Modified constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint‐induced movement therapy (kid‐CIMT)
Study: 17323661
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.1 ml/kg (Group NS)
Study: 17323661
Drug: Lignocaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1.5 mg/kg (Group L)
Study: 9591761
Drug: abciximab (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (0.25 mg/kg bolus and 12-hour infusion of 10 microg/min, EPIC regimen)
Study: 9591761
Drug: abciximab (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (0.25 mg/kg bolus and 12-hour infusion of 0.125 microg x kg(‐1) x min(‐1), EPILOG regimen)
Study: 8201150
Drug: KC‐764 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: KC‐764 10 mg/day
Study: 8201150
Drug: KC‐764 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: KC‐764 20 mg/day
Study: 8201150
Drug: KC‐764 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: KC‐764 40 mg/day
Study: 8201150
Drug: KC‐764 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: KC‐764 (all doses)
Study: 3310633
Drug: Sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2 g at night
Study: 30742513
Drug: 2-hour workshop
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-hour workshop on compression therapy (n = 14)
Study: 10516941
Drug: Ciclesonide nasal
Normalized name: ciclesonide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide nasal spray (200 micrograms per nostril)
Study: 31116017
Drug: Computer-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based cognitive behavioral therapy
Study: 2038242
Drug: Therapist-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-based cognitive behavioral therapy
Study: 24183563
Drug: Pimavanserin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin 40 mg per day
Study: 9564797
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg total daily dose
Study: 9564797
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg total daily dose
Study: 9564797
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 microg total daily dose
Study: 9564797
Drug: Budesonide 1600
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 1600 microg total daily dose
Study: 2500670
Drug: Enprostil 35-140
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil 35-140 mcg (acute)
Study: 2500670
Drug: Enprostil 35
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil 35 mcg or 70 mcg BID (chronic)
Study: 22784037
Drug: Once-daily tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tenofovir (TDF)
Study: 22784037
Drug: Combination tenofovir‐emtricitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tenofovir‐emtricitabine (TDF‐FTC)
Study: 12678539
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate ointment (0.2% twice daily) applied to the perianal area
Study: 12678539
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied to the perianal area
Study: 3191944
Drug: Sertraline 25
Normalized name: sertraline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 25 mg
Study: 3191944
Drug: Sertraline 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 75 mg
Study: 25457977
Drug: Chiropractic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic manipulative therapy (MT) plus rehabilitation
Study: 23237514
Drug: Anti-stretch mark
Normalized name: Mederma Stretch Mark Therapy
DrugBank: Glycyrrhizic acid (DB13751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-stretch mark cream containing hydroxyprolisilane-C, rosehip oil, Centella asiatica triterpenes and vitamin E
Study: 23237514
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (cream without active ingredients)
Study: 21529979
Drug: Routine Glutamic
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Routine Glutamic Acid Decarboxylase Antibody (GADA) testing
Study: 16823248
Drug: Carvedilol (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12.5 mg/day for the first 2 days, then 25 mg/day for 90 days)
Study: 16823248
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg/day for 90 days)
Study: 16823248
Drug: Doxazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (2 mg/day for 90 days)
Study: 10799347
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg valerian and 120 mg hops (low dosage)
Study: 10799347
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg valerian and 360 mg hops (high dosage)
Study: 9404921
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (busulfan 16 mg/kg, etoposide 40 mg/kg, cytosine arabinoside 3 g/m2 x 4) followed by autologous peripheral blood stem cell transplantation (ABSCT) in 13 patients.
Study: 9404921
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) administered concurrently with the BEA regimen during conditioning in 47 patients.
Study: 8362632
Drug: Erythromycin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1000 mg/day for 10 days) in Group A
Study: 8362632
Drug: Roxithromycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (300 mg/day for 10 days) in Group B
Study: 8362632
Drug: Erythromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1 g/day for 14 days) in Group C
Study: 3750135
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine 1.5 mg/kg 4‐6‐hourly as required
Study: 20229000
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg kg(‐1) (small-dose group, n = 12)
Study: 20229000
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg kg(‐1) (large-dose group, n = 12)
Study: 20229000
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of midazolam (0.2 and 0.3 mg kg(‐1))
Study: 18520802
Drug: PPX/carboplatin (PPX
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPX/carboplatin (PPX 210 mg/m/10 min without routine steroid premedication)
Study: 18520802
Drug: Paclitaxel/carboplatin (Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel/carboplatin (Paclitaxel 225 mg/m/3 h with standard premedication)
Study: 3526617
Drug: Corinfar administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corinfar administered sublingually at a dose of 10-30 mg
Study: 31262371
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g n‐3 PUFA daily for 3 months
Study: 31262371
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g n‐3 PUFA daily for 3 months (after washout)
Study: 15372589
Drug: entacapone 200
Normalized name: entacapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: entacapone 200 mg
Study: 15372589
Drug: entacapone 400
Normalized name: Entacapone
DrugBank: Entacapone (DB00494)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: entacapone 400 mg
Study: 15372589
Drug: entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: entacapone (200 mg and 400 mg)
Study: 11203847
Drug: Core build-ups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core build-ups (all materials) after crown preparation
Study: 11203847
Drug: Amalgam core
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amalgam core build-ups after crown preparation
Study: 3510594
Drug: Cold potassium
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold potassium cardioplegia with St. Thomas' Hospital solution (Group 1)
Study: 31006007
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (EPA and DHA) at doses reflecting 1, 2, or 4 portions of oily fish per week (3.27 g EPA + DHA per portion)
Study: 28671082
Drug: Zhuang medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhuang medicine medicated thread moxibustion
Study: 24012033
Drug: Intravenous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoxaparin
Study: 21127284
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg levobupivacaine + 10 μg fentanyl
Study: 21127284
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg levobupivacaine + 10 μg fentanyl
Study: 21127284
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg levobupivacaine + 10 μg fentanyl
Study: 16820547
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg twice daily, n = 344)
Study: 16820547
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 mg twice daily, n = 342)
Study: 10886201
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravenous vitamin K
Study: 10886201
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intravenous vitamin K
Study: 10886201
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravenous vitamin K
Study: 9039339
Drug: Oral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestrogen replacement therapy (17 beta-oestradiol 2 mg daily on days 1-22 and 1 mg daily on days 23-28, norethisterone 1 mg days 13-22)
Study: 9039339
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen replacement therapy (oestradiol 50 micrograms/24 h on days 1-28, norethisterone 250 micrograms/24 h on days 15-28)
Study: 1554119
Drug: Transdermal 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 10% lidocaine gel with 3% glycyrrhetinic acid monohemiphthalate disodium (GAMHPh)
Study: 1554119
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Transdermal 10% lidocaine gel without GAMHPh)
Study: 27246516
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation programme combining multimodal exercises with psychologist‐lead cognitive‐behavioural therapy sessions
Study: 25676529
Drug: Rivaroxaban (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (with prestudy heparin)
Study: 25676529
Drug: Enoxaparin/VKA (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin/VKA (with prestudy heparin)
Study: 25676529
Drug: Rivaroxaban (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (without prestudy heparin)
Study: 25676529
Drug: Enoxaparin/VKA (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin/VKA (without prestudy heparin)
Study: 17999429
Drug: BTX‐B (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐B (20 U, 100 U, or 500 U/0.2 mL)
Study: 16206608
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (i.v. prospidin 200‐300 mg/week + i.m. methotrexate 10 mg/week)
Study: 16206608
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy (10 mg/week i.m.)